Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.
1. India’s Central Drug Licensing authority has mandated to file all Post Approval Change (Form CT-06) applications for Cell and Gene Therapeutic Products exclusively through the SUGAM online portal after October 24 2025. Offline submissions will no longer be accepted thereafter.
Source: urli.info/1e0FX
2. The Indian Pharmacopoeia Commission has reportedly introduced 22 quality standards for blood and its components to ensure safe transfusions across India. These standards, to be included in the Indian Pharmacopoeia 2026, establish globally first comprehensive benchmarks ensuring quality, safety, and infection-free blood for patients nationwide.
Source: urli.info/1iNpx
3. The Ministry of Health and Family Welfare has issued draft amendments to the Drugs Rules, 1945, introducing provisions to debar applicants found submitting misleading, fake, or fabricated documents for licences or approvals. Offenders may face suspension for a defined period, with the right to appeal within 30 days. Stakeholder comments invited within 30 days of publication.
Source: urli.info/1e0Fx
4. The Delhi High Court held that a doctor accused of medical negligence can continue to earn a livelihood by working at other medical centres. The Court clarified that the restriction only bars the doctor from running their own centre and does not prevent them from practising their profession elsewhere.
Source: urli.info/1e0FN
5. A Consumer Dispute Redressal Forum in India has held that the absence of a pathologist’s physical signature on medical reports cannot alone justify the denial of an insurance claim. In a case where a policyholder’s claim was rejected due to a missing signature, the forum directed the insurer to reimburse the cost after finding no evidence of fraud.
Source: urli.info/1iNph
